

# Gastrointestinal Therapeutics-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/G399F6A15B7MEN.html>

Date: March 2018

Pages: 136

Price: US\$ 3,480.00 (Single User License)

ID: G399F6A15B7MEN

## Abstracts

### Report Summary

Gastrointestinal Therapeutics-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Gastrointestinal Therapeutics industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Gastrointestinal Therapeutics 2013-2017, and development forecast 2018-2023

Main market players of Gastrointestinal Therapeutics in EMEA, with company and product introduction, position in the Gastrointestinal Therapeutics market

Market status and development trend of Gastrointestinal Therapeutics by types and applications

Cost and profit status of Gastrointestinal Therapeutics, and marketing status

Market growth drivers and challenges

The report segments the EMEA Gastrointestinal Therapeutics market as:

EMEA Gastrointestinal Therapeutics Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Gastrointestinal Therapeutics Market: Product Type Segment Analysis

(Consumption Volume, Average Price, Revenue, Market Share and Trend  
2013-2023):

Tablets  
Injection

EMEA Gastrointestinal Therapeutics Market: Application Segment Analysis  
(Consumption Volume and Market Share 2013-2023; Downstream Customers and  
Market Analysis)

IBD  
Irritable Bowel Syndrome (IBS)  
Other

EMEA Gastrointestinal Therapeutics Market: Players Segment Analysis (Company and  
Product introduction, Gastrointestinal Therapeutics Sales Volume, Revenue, Price and  
Gross Margin):

Johnson & Johnson  
AbbVie  
Allergan  
Takeda  
Novartis  
Pfizer  
GlaxoSmithKline  
Merck  
UCB (Belgium)  
F. Hoffmann-La Roche  
Eli Lilly  
AstraZeneca  
Procter & Gamble  
Eisai  
Shire Pharmaceuticals  
Ferring Pharmaceuticals  
Kyowa Hakko Kirin  
Salix Pharmaceuticals  
Ono Pharmaceutical  
TSD Japan  
RedHill Biopharma  
Kaken Pharmaceutical  
Amgen  
Synergy Pharmaceuticals

Ajinomoto  
Kissei Pharmaceutical  
Hutchison Medi Pharma

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF GASTROINTESTINAL THERAPEUTICS**

- 1.1 Definition of Gastrointestinal Therapeutics in This Report
- 1.2 Commercial Types of Gastrointestinal Therapeutics
  - 1.2.1 Tablets
  - 1.2.2 Injection
- 1.3 Downstream Application of Gastrointestinal Therapeutics
  - 1.3.1 IBD
  - 1.3.2 Irritable Bowel Syndrome (IBS)
  - 1.3.3 Other
- 1.4 Development History of Gastrointestinal Therapeutics
- 1.5 Market Status and Trend of Gastrointestinal Therapeutics 2013-2023
  - 1.5.1 EMEA Gastrointestinal Therapeutics Market Status and Trend 2013-2023
  - 1.5.2 Regional Gastrointestinal Therapeutics Market Status and Trend 2013-2023

### **CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Gastrointestinal Therapeutics in EMEA 2013-2017
- 2.2 Consumption Market of Gastrointestinal Therapeutics in EMEA by Regions
  - 2.2.1 Consumption Volume of Gastrointestinal Therapeutics in EMEA by Regions
  - 2.2.2 Revenue of Gastrointestinal Therapeutics in EMEA by Regions
- 2.3 Market Analysis of Gastrointestinal Therapeutics in EMEA by Regions
  - 2.3.1 Market Analysis of Gastrointestinal Therapeutics in Europe 2013-2017
  - 2.3.2 Market Analysis of Gastrointestinal Therapeutics in Middle East 2013-2017
  - 2.3.3 Market Analysis of Gastrointestinal Therapeutics in Africa 2013-2017
- 2.4 Market Development Forecast of Gastrointestinal Therapeutics in EMEA 2018-2023
  - 2.4.1 Market Development Forecast of Gastrointestinal Therapeutics in EMEA 2018-2023
  - 2.4.2 Market Development Forecast of Gastrointestinal Therapeutics by Regions 2018-2023

### **CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Whole EMEA Market Status by Types
  - 3.1.1 Consumption Volume of Gastrointestinal Therapeutics in EMEA by Types
  - 3.1.2 Revenue of Gastrointestinal Therapeutics in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries

- 3.2.1 Market Status by Types in Europe
- 3.2.2 Market Status by Types in Middle East
- 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Gastrointestinal Therapeutics in EMEA by Types

## **CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of Gastrointestinal Therapeutics in EMEA by Downstream Industry
- 4.2 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Major Countries
  - 4.2.1 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Europe
  - 4.2.2 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Middle East
  - 4.2.3 Demand Volume of Gastrointestinal Therapeutics by Downstream Industry in Africa
- 4.3 Market Forecast of Gastrointestinal Therapeutics in EMEA by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF GASTROINTESTINAL THERAPEUTICS**

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Gastrointestinal Therapeutics Downstream Industry Situation and Trend Overview

## **CHAPTER 6 GASTROINTESTINAL THERAPEUTICS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA**

- 6.1 Sales Volume of Gastrointestinal Therapeutics in EMEA by Major Players
- 6.2 Revenue of Gastrointestinal Therapeutics in EMEA by Major Players
- 6.3 Basic Information of Gastrointestinal Therapeutics by Major Players
  - 6.3.1 Headquarters Location and Established Time of Gastrointestinal Therapeutics Major Players
  - 6.3.2 Employees and Revenue Level of Gastrointestinal Therapeutics Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 GASTROINTESTINAL THERAPEUTICS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

### 7.1 Johnson & Johnson

#### 7.1.1 Company profile

#### 7.1.2 Representative Gastrointestinal Therapeutics Product

#### 7.1.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Johnson & Johnson

### 7.2 AbbVie

#### 7.2.1 Company profile

#### 7.2.2 Representative Gastrointestinal Therapeutics Product

#### 7.2.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of AbbVie

### 7.3 Allergan

#### 7.3.1 Company profile

#### 7.3.2 Representative Gastrointestinal Therapeutics Product

#### 7.3.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Allergan

### 7.4 Takeda

#### 7.4.1 Company profile

#### 7.4.2 Representative Gastrointestinal Therapeutics Product

#### 7.4.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Takeda

### 7.5 Novartis

#### 7.5.1 Company profile

#### 7.5.2 Representative Gastrointestinal Therapeutics Product

#### 7.5.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Novartis

### 7.6 Pfizer

#### 7.6.1 Company profile

#### 7.6.2 Representative Gastrointestinal Therapeutics Product

#### 7.6.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Pfizer

### 7.7 GlaxoSmithKline

#### 7.7.1 Company profile

#### 7.7.2 Representative Gastrointestinal Therapeutics Product

#### 7.7.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of GlaxoSmithKline

### 7.8 Merck

#### 7.8.1 Company profile

- 7.8.2 Representative Gastrointestinal Therapeutics Product
- 7.8.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Merck
- 7.9 UCB (Belgium)
  - 7.9.1 Company profile
  - 7.9.2 Representative Gastrointestinal Therapeutics Product
  - 7.9.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of UCB (Belgium)
- 7.10 F. Hoffmann-La Roche
  - 7.10.1 Company profile
  - 7.10.2 Representative Gastrointestinal Therapeutics Product
  - 7.10.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche
- 7.11 Eli Lilly
  - 7.11.1 Company profile
  - 7.11.2 Representative Gastrointestinal Therapeutics Product
  - 7.11.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.12 AstraZeneca
  - 7.12.1 Company profile
  - 7.12.2 Representative Gastrointestinal Therapeutics Product
  - 7.12.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca
- 7.13 Procter & Gamble
  - 7.13.1 Company profile
  - 7.13.2 Representative Gastrointestinal Therapeutics Product
  - 7.13.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Procter & Gamble
- 7.14 Eisai
  - 7.14.1 Company profile
  - 7.14.2 Representative Gastrointestinal Therapeutics Product
  - 7.14.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Eisai
- 7.15 Shire Pharmaceuticals
  - 7.15.1 Company profile
  - 7.15.2 Representative Gastrointestinal Therapeutics Product
  - 7.15.3 Gastrointestinal Therapeutics Sales, Revenue, Price and Gross Margin of Shire Pharmaceuticals
- 7.16 Ferring Pharmaceuticals
- 7.17 Kyowa Hakko Kirin
- 7.18 Salix Pharmaceuticals

- 7.19 Ono Pharmaceutical
- 7.20 TSD Japan
- 7.21 RedHill Biopharma
- 7.22 Kaken Pharmaceutical
- 7.23 Amgen
- 7.24 Synergy Pharmaceuticals
- 7.25 Ajinomoto
- 7.26 Kissei Pharmaceutical
- 7.27 Hutchison Medi Pharma

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF GASTROINTESTINAL THERAPEUTICS**

- 8.1 Industry Chain of Gastrointestinal Therapeutics
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF GASTROINTESTINAL THERAPEUTICS**

- 9.1 Cost Structure Analysis of Gastrointestinal Therapeutics
- 9.2 Raw Materials Cost Analysis of Gastrointestinal Therapeutics
- 9.3 Labor Cost Analysis of Gastrointestinal Therapeutics
- 9.4 Manufacturing Expenses Analysis of Gastrointestinal Therapeutics

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF GASTROINTESTINAL THERAPEUTICS**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**



## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

### 12.1 Methodology/Research Approach

#### 12.1.1 Research Programs/Design

#### 12.1.2 Market Size Estimation

#### 12.1.3 Market Breakdown and Data Triangulation

### 12.2 Data Source

#### 12.2.1 Secondary Sources

#### 12.2.2 Primary Sources

### 12.3 Reference

## I would like to order

Product name: Gastrointestinal Therapeutics-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/G399F6A15B7MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G399F6A15B7MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970